title: [Low prevalence of hepatitis B virus primary drug resistance in Southern Spain].
abstract: BACKGROUND
  To know the prevalence of primary resistance in chronic hepatitis B naïve patients is essential to decide on the need of routine laboratory testing.
  
  
  METHODS
  The genetic sequence of the HBV polymerase from 105naïve patients was analysed.
  
  
  RESULTS
  rtV173L, a lamivudine compensatory mutation, was detected in two patients (1.9%), rtI233V in one patient, and another one carried the sG145R vaccine escape mutation.
  
  
  CONCLUSIONS
  Our study shows that studying HBV resistance in naïve patients should not be recommended in the routine laboratory setting, for the time being.
authors.affiliation: Servicio de Microbiología, Hospital San Cecilio, Granada, España. Electronic address: martaalvest@yahoo.es.
authors.forename: Marta
authors.initials: M
authors.lastname: Alvarez Estévez
authors.forename: Natalia
authors.initials: N
authors.lastname: Chueca-Porcuna
authors.forename: Vicente
authors.initials: V
authors.lastname: Guillot-Suay
authors.forename: Alejandro
authors.initials: A
authors.lastname: Peña-Monje
authors.forename: Fernando
authors.initials: F
authors.lastname: García-García
authors.forename: Federico
authors.initials: F
authors.lastname: García-García
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000998:Antiviral Agents / Q000494:pharmacology*; D002648:Child; D002675:Child, Preschool; D024882:Drug Resistance, Viral / Q000235:genetics; D005260:Female; D015684:Gene Products, pol / Q000235:genetics; D005814:Genes, Viral; D017325:Hepatitis B Vaccines; D006515:Hepatitis B virus / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D019694:Hepatitis B, Chronic / Q000453:epidemiology / Q000821:virology; D006801:Humans; D019259:Lamivudine / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D020125:Mutation, Missense; D017354:Point Mutation; D015995:Prevalence; D011446:Prospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology; D013030:Spain / Q000453:epidemiology; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D015684:Gene Products, pol; D017325:Hepatitis B Vaccines; C066027:P protein, Hepatitis B virus; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine
keywords: Hepatitis B virus; Primary drug resistance; Resistencias primarias; Secuenciación; Sequencing; Virus de la hepatitis B